



ONLINE-ONLY MATERIAL**Supplementary Methods****Study oversight**

F. Hoffmann-La Roche, Ltd./Genentech, Inc., sponsored the study, provided the study drugs, and collaborated with the academic authors regarding the study design and data collection, analysis, and interpretation. All drafts of the manuscript were prepared by the authors, with editorial assistance from a professional medical writer funded by the sponsor. All authors approved submission. All authors verify that the study was conducted per protocol (available with the statistical analysis plan online) and vouch for the data accuracy and completeness.


Supplementary Figure S1. Percent change in sum of longest diameters. FP only by study day. Only RECIST target lesions were included.



Supplementary Figure S2. Exploratory association of baseline characteristics. Comparison of baseline characteristics between atezolizumab-treated patients with fast progression (FP) and without (*A*) and between docetaxel-treated patients with FP and without (*B*). Percentages were calculated from patients with nonmissing data (see **Supplementary Table S1**). bTMB, blood-based tumor mutational burden; ECOG PS, Eastern Cooperative Oncology Group performance status; *EGFR*, epidermal growth factor receptor; LDH, lactate dehydrogenase; *MDM2*, murine double minute 2 homolog; PD-L1, programmed death-ligand 1; SLD, sum of largest diameters.


A Comparison of baseline characteristics between atezolizumab-treated patients with FP and without

Confidential | Not for distribution | Page 4 of 8


B Comparison of baseline characteristics between docetaxel-treated patients with FP and without

Supplementary Figure S3. Kaplan-Meier plots of overall survival (OS) in clinically relevant patient subgroups. 1L, first line; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.


A OS for failure of preceding 1L treatment ≤ 6 months




B OS for failure of preceding 1L treatment >6 months




C OS for ≥3 metastatic sites



D OS for <3 metastatic sites



E OS for ECOG PS 1



F OS for ECOG PS 0

